AR130952A1 - Formulación oral de un derivado de n-piridinil acetamida - Google Patents
Formulación oral de un derivado de n-piridinil acetamidaInfo
- Publication number
- AR130952A1 AR130952A1 ARP230102947A ARP230102947A AR130952A1 AR 130952 A1 AR130952 A1 AR 130952A1 AR P230102947 A ARP230102947 A AR P230102947A AR P230102947 A ARP230102947 A AR P230102947A AR 130952 A1 AR130952 A1 AR 130952A1
- Authority
- AR
- Argentina
- Prior art keywords
- oral formulation
- acetamide derivative
- pyridyl
- subject
- lung disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicación 1: Un método para tratar la enfermedad pulmonar intersticial en un sujeto que lo necesite, que comprende administrar por vía oral al sujeto 2-[4-(2-metil-4-piridil)pirrolo[3,2-c]piridin-1-il]-N-(5-pirazin-2-il-2-piridil)acetamida (AZD5055): de fórmula (1) en una dosis de entre 5 y 35 mg al día. Reivindicación 13: El método según una cualquiera de las reivindicaciones 1 a 12, que comprende adicionalmente la administración separada, secuencial o simultánea de un inhibidor de la bomba de protones o una sal farmacéuticamente aceptable del mismo. Reivindicación 14: El método según la reivindicación 13, en donde el inhibidor de la bomba de protones es rabeprazol. Reivindicación 16: El método según una cualquiera de las reivindicaciones 1 a 15, en donde la enfermedad pulmonar intersticial es fibrosis pulmonar idiopática.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263382311P | 2022-11-04 | 2022-11-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR130952A1 true AR130952A1 (es) | 2025-02-05 |
Family
ID=88689993
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230102947A AR130952A1 (es) | 2022-11-04 | 2023-11-03 | Formulación oral de un derivado de n-piridinil acetamida |
Country Status (14)
| Country | Link |
|---|---|
| JP (1) | JP2025536575A (es) |
| KR (1) | KR20250099240A (es) |
| CN (1) | CN120187430A (es) |
| AR (1) | AR130952A1 (es) |
| AU (1) | AU2023374727A1 (es) |
| CL (1) | CL2025001306A1 (es) |
| CO (1) | CO2025007400A2 (es) |
| CR (1) | CR20250229A (es) |
| DO (1) | DOP2025000103A (es) |
| IL (1) | IL320576A (es) |
| MX (1) | MX2025005174A (es) |
| PE (1) | PE20251575A1 (es) |
| TW (1) | TW202434248A (es) |
| WO (1) | WO2024094844A1 (es) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112017007218B1 (pt) | 2014-10-08 | 2023-10-10 | Redx Pharma Plc | Derivados de n-piridil acetamida como inibidores da via de sinalização de wnt, formulações farmacêuticas compreendendo os mesmos e seus usos |
-
2023
- 2023-11-03 CN CN202380078161.XA patent/CN120187430A/zh active Pending
- 2023-11-03 WO PCT/EP2023/080652 patent/WO2024094844A1/en not_active Ceased
- 2023-11-03 TW TW112142363A patent/TW202434248A/zh unknown
- 2023-11-03 AU AU2023374727A patent/AU2023374727A1/en active Pending
- 2023-11-03 CR CR20250229A patent/CR20250229A/es unknown
- 2023-11-03 JP JP2025524809A patent/JP2025536575A/ja active Pending
- 2023-11-03 PE PE2025000928A patent/PE20251575A1/es unknown
- 2023-11-03 KR KR1020257018380A patent/KR20250099240A/ko active Pending
- 2023-11-03 AR ARP230102947A patent/AR130952A1/es unknown
-
2025
- 2025-04-29 IL IL320576A patent/IL320576A/en unknown
- 2025-05-02 DO DO2025000103A patent/DOP2025000103A/es unknown
- 2025-05-02 CL CL2025001306A patent/CL2025001306A1/es unknown
- 2025-05-02 MX MX2025005174A patent/MX2025005174A/es unknown
- 2025-06-03 CO CONC2025/0007400A patent/CO2025007400A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202434248A (zh) | 2024-09-01 |
| CR20250229A (es) | 2025-07-11 |
| DOP2025000103A (es) | 2025-06-15 |
| CL2025001306A1 (es) | 2025-08-01 |
| WO2024094844A1 (en) | 2024-05-10 |
| KR20250099240A (ko) | 2025-07-01 |
| PE20251575A1 (es) | 2025-06-12 |
| CN120187430A (zh) | 2025-06-20 |
| JP2025536575A (ja) | 2025-11-07 |
| CO2025007400A2 (es) | 2025-06-16 |
| MX2025005174A (es) | 2025-06-02 |
| AU2023374727A1 (en) | 2025-06-19 |
| IL320576A (en) | 2025-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2518418T3 (es) | Composiciones de vasoconstricción y métodos de uso | |
| US11786496B2 (en) | Composition and methods for treating intestinal hyperpermeability | |
| HUP0204079A2 (hu) | Szedatív hatástól mentes antihisztaminok és leukotrién hatást befolyásoló anyagok új kombinációja orrnyálkahártya-gyulladás, vagy kötőhártya-gyulladás kezelésére | |
| AU2004233587B2 (en) | Use of a topical medicament comprising Riluzole | |
| JP5780430B2 (ja) | 勃起不全の処置用のPDE5阻害剤と組み合わせたsGC刺激剤またはsGC活性化剤 | |
| KR102689822B1 (ko) | 코로나바이러스의 치료 방법 | |
| CA2304162A1 (en) | Use of combinations comprising non-sedating antihistamines and alpha-adrenergic drugs for the topical treatment of rhinitis/conjunctivitis and cold, cold-like and/or flu symptoms | |
| CN113893239A (zh) | 用于治疗肠渗透性过高的酪氨酸羟化酶抑制剂 | |
| JP2024102113A (ja) | 毛髪の成長を刺激するためのアルファ-ケトブチレート、アルファ-ケトグルタレート、および2-ヒドロキシブチレート | |
| ES2551752T3 (es) | Composiciones de bepotastina | |
| US9408831B2 (en) | Methods for treating respiratory viral infection | |
| CL2024001530A1 (es) | Nuevas combinaciones terapéuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas | |
| CL2024003616A1 (es) | Composición farmacéutica oral y uso para la terapia de enfermedades pulmonares intersticiales fibrosantes progresivas. | |
| JP2014224143A (ja) | 他の薬剤と組合せた(r,r)−ホルモテロール | |
| KR20070048199A (ko) | 바이러스의 억제, 파괴 및/또는 불활성화를 위한 방법 및조성물 | |
| TW202106690A (zh) | 皮膚型紅斑狼瘡之治療 | |
| UA123780C2 (uk) | Лікування екземи кистей | |
| CN111821299A (zh) | 噻吩衍生物用于治疗免疫球蛋白E(IgE)介导的疾病的应用 | |
| CN104324018A (zh) | 广藿香醇在制备男性性功能障碍药物或保健品中的应用 | |
| JP2008542290A (ja) | 皮膚狼瘡の治療又は予防のための4−[(シクロプロパンカルボニルアミノ)メチル]−2−(2,6−ジオキソピペリジン−3−イル)イソインドール−1,3−ジオンの使用方法及び組成物 | |
| JP5800485B2 (ja) | 鼻汁分泌抑制用組成物 | |
| JP2017505350A (ja) | 硫黄含有部分を含む糖誘導体ならびにその作製方法およびmps iiicの処置のためのその使用方法 | |
| PE20251575A1 (es) | Formulacion oral de derivado de n-piridinilacetamida para tratar la enfermedad pulmonar intersticial | |
| AR118056A2 (es) | Formulaciones de inhibidor de histona desacetilasa en combinación con bendamustina y uso de las mismas | |
| CN105873611A (zh) | 利用pde4调节剂治疗病毒性疾病的组合物和方法 |